Page 5 - Heart Failure Guidelines

 

 

 

 

 

Page 5 - Heart Failure Guidelines
P. 5

Pediatric Heart Failure Guidelines

                  Medical Management Chemotherapy Induced Cardiomyopathy ............................................25
                  Follow-up Schedule for Chemotherapy Induced Cardiomyopathy ..........................................25
               Neuromuscular Disorder Associated Cardiomyopathy ..............................................................26

                  Additional Evaluation for Patient with Neuromuscular Disorder associated Cardiomyopathy .26
               Introduction ...............................................................................................................................26
               Initial Evaluation ........................................................................................................................26
               Ongoing Management ...............................................................................................................26

                  Dose escalation plan (outpatient monitoring) .........................................................................27
               Imaging .....................................................................................................................................28
               Arrhythmia Screening ................................................................................................................28
               Advanced Therapies .................................................................................................................28
               Myocarditis ................................................................................................................................29
                  Additional Evaluation for possible Myocarditis .......................................................................29
                  Medical Management Myocarditis .........................................................................................29
                  Immunotherapy Management Myocarditis .............................................................................29
                  Follow-up Schedule for Myocarditis .......................................................................................30

               Medication Doses .....................................................................................................................31
               Anticoagulation Schedules ........................................................................................................33












































               Updated 7/31/2018                                                                       page 5
   1   2   3   4   5   6   7   8   9   10